ライフサイエンスコーパス: pasireotide

1 tive administration of pasireotide versus no pasireotide.

2 es including ketoconazole, mifepristone, and pasireotide.

3 hepatic hypertrophy that can be corrected by pasireotide.

4 profile to that of twice-daily subcutaneous pasireotide.

5 oximately 50% when SBI-115 was combined with pasireotide.

6 e randomly allocated 150 patients to receive pasireotide 10 mg (74 [49%] patients) or 30 mg (76 [51%]

7 -response-technology system to intramuscular pasireotide 10 mg or 30 mg every 4 weeks for 12 months (

8 patients to receive 900 mug of subcutaneous pasireotide (152 patients) or placebo (148 patients) twi

9 glycaemia (21 [33%] for treatment with 40 mg pasireotide, 19 [31%] with 60 mg pasireotide, and nine [

10 ients were enrolled and randomly assigned to pasireotide 40 mg (n=65), pasireotide 60 mg (n=65), or a

11 At 24 weeks, ten (15%) patients in the pasireotide 40 mg group and 13 (20%) patients in the pas

12 l group 15.4%, 95% CI 7.6-26.5, p=0.0006 for pasireotide 40 mg group, 20.0%, 11.1-31.8, p<0.0001 for

13 s were reported in six (10%) patients in the pasireotide 40 mg group, two (3%) in the pasireotide 60

14 e cost neutral, either the purchase price of pasireotide ($43,172) must be reduced by 92.3% (to $3324

15 ndomly assigned to pasireotide 40 mg (n=65), pasireotide 60 mg (n=65), or active control (n=68) group

16 ide 40 mg group and 13 (20%) patients in the pasireotide 60 mg group achieved biochemical control, co

17 40 mg group, 20.0%, 11.1-31.8, p<0.0001 for pasireotide 60 mg group).

18 the pasireotide 40 mg group, two (3%) in the pasireotide 60 mg group, and three (5%) in the active co

19 1:1:1) to receive treatment with long-acting pasireotide (60 mg intramuscularly every 28 days), evero

20 Pasireotide, a potential therapy, has a unique, broad so

21 Pasireotide, a somatostatin analogue that has a longer h

22 -115]), and (3) a combination of SBI-115 and pasireotide, a somatostatin receptor analogue.

23 Pasireotide, a therapeutic cyclic peptide, exhibits poor

24 fectiveness model was constructed to compare pasireotide administration after pancreatic resection ve

25 Treatment with tolvaptan or pasireotide alone markedly reduced cyst progression and

26 ssess the efficacy and safety of long-acting pasireotide and everolimus, administered alone or in com

27 with 40 mg pasireotide, 19 [31%] with 60 mg pasireotide, and nine [14%] with active control), diabet

28 Pasireotide appears to be a cost-saving treatment follow

29 timately determine the utility of widespread pasireotide application in pancreatic resection.

30 of the normal range to receive subcutaneous pasireotide at a dose of 600 mug (82 patients) or 900 mu

31 Without considering pasireotide cost, prophylactic use of the drug saved an

32 Perioperative treatment with pasireotide decreased the rate of clinically significant

33 to study drug assignment but were masked to pasireotide dose allocation.

34 ctiveness of perioperative administration of pasireotide for reduction of pancreatic fistula (PF).

35 (39.0%, 95% CI 24.2-55.5) in the long-acting pasireotide group, 14 of 42 patients (33.3%, 19.6-49.5)

36 ntries: 41 were allocated to the long-acting pasireotide group, 42 to the everolimus group, and 41 to

37 sure date: two (5%) of 41 in the long-acting pasireotide group, six (14%) of 42 in the everolimus gro

38 C-DMS-MIM assay for quantitative analysis of pasireotide in human plasma was evaluated and compared t

39 le-blind trial of perioperative subcutaneous pasireotide in patients undergoing either pancreaticoduo

40 y significant POPF with use of perioperative pasireotide in patients undergoing pancreaticoduodenecto

41 3 trial assessing long-acting intramuscular pasireotide in patients with Cushing's disease.

42 Pasireotide is a novel multireceptor ligand somatostatin

43 analyses demonstrate that when prophylactic pasireotide is administered, the cost per PF/PL/A avoide

44 Long-acting pasireotide is an efficacious treatment option for some

45 different doses of the somatostatin analogue pasireotide long-acting release compared with active con

46 e voice-web response system to receive 40 mg pasireotide long-acting release once every 28 days for 2

47 lease once every 28 days for 24 weeks, 60 mg pasireotide long-acting release once every 28 days for 2

48 ith a suspected association with long-acting pasireotide monotherapy were diarrhoea (15 [37%] of 41),

49 ith a suspected association with long-acting pasireotide monotherapy were gamma-glutamyltransferase i

50 this did not reach statistical significance (pasireotide, MP$22,800 vs placebo, MP$23,900: P = 0.571)

51 The mean cost was lower in the pasireotide (n = 152) group than the placebo (n = 148) g

52 duodenectomy or distal pancreatectomy [POPF: pasireotide (n = 152), 9% vs placebo (n = 148), 21%; P =

53 INTERPRETATION: Long-acting pasireotide normalised mUFC concentration in about 40% o

54 Here we compare the effects of OCT to pasireotide (PAS; a more potent somatostatin analog with

55 s analysis to determine whether prophylactic pasireotide possesses a reasonable cost profile by impro

56 Pasireotide provides superior efficacy compared with con

57 In this randomized trial, the routine use of pasireotide significantly reduced the occurrence of POPF

58 ted for quantitative LC-MS/MS bioanalysis of pasireotide (SOM230) in human plasma.

59 patients with Cushing's disease who received pasireotide supports its potential use as a targeted tre

60 nificantly lower among patients who received pasireotide than among patients who received placebo (9%

61 t-effectiveness of routine administration of pasireotide to patients undergoing PD, compared with no

62 Exclusion criteria included previous pasireotide treatment, mitotane therapy within 6 months,

63 were suspected to be related to long-acting pasireotide treatment.

64 o evaluate the cost-effectiveness of routine pasireotide use.

65 re costs for perioperative administration of pasireotide versus no pasireotide.

66 Pasireotide was associated with hyperglycemia-related ad

67 Relative risk of PF associated with pasireotide was estimated from the published literature.

68 However, when the cost of pasireotide was included, per patient costs increased fr

69 Pasireotide was recently shown to decrease leak rates af

70 Pasireotide was the dominant strategy, associated with s

71 Compounds such as tolvaptan and pasireotide, which indirectly reduce adenylyl cyclase 6

72 Human plasma was spiked with pasireotide with concentrations in the range 0.01-50 ng/

73 The mean cost of pasireotide within the treatment group (n = 152) was MP$